Irbesartan Micro Labs (Irbesartan)

Irbesartan is an Angiotensin II receptor blocker used in several cardiovascular and renal conditions.

• Hypertension: reduces systolic and diastolic blood pressure, lowering cardiovascular risk.
• Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes.
• Heart failure: improves symptoms and reduces hospitalizations in patients with left‑ventricular dysfunction.

• Irbesartan selectively blocks the binding of angiotensin II to AT1 receptors on vascular smooth‑muscle cells, adrenal glands and the kidney. By preventing receptor activation, it inhibits vasoconstriction, aldosterone secretion and sympathetic stimulation, leading to vasodilation, reduced sodium‑water retention and lower blood pressure. The blockade also reduces pathological remodeling of the heart and kidneys, contributing to its benefits in heart failure and diabetic nephropathy.

Irbesartan may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate intensity.
• Fatigue: feeling of tiredness or lack of energy.
• Nasal congestion: blocked or runny nose.
• Diarrhea: loose stools.

Serious or Rare Side Effects

• Hyperkalemia: elevated blood potassium levels, potentially dangerous.
• Renal impairment: worsening kidney function, indicated by increased creatinine.
• Angioedema: swelling of face, lips, tongue or throat.
• Hepatic injury: abnormal liver enzymes or hepatitis.
• Severe hypotension: marked drop in blood pressure causing fainting.

When prescribing Irbesartan, clinicians should consider several safety measures.

• Pregnancy: contraindicated in the second and third trimesters due to fetal toxicity (Category D).
• Renal function: monitor serum creatinine and potassium, especially in patients with pre‑existing kidney disease.
• Concomitant potassium‑sparing diuretics: avoid or monitor for hyperkalemia.
• Hepatic impairment: use with caution; dose adjustment may be required.
• Elderly patients: start at lower dose and monitor blood pressure closely.
• Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Irbesartan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• ACE inhibitors or aliskiren: combined use may cause excessive potassium rise and renal dysfunction.
• Potassium supplements or potassium‑sparing diuretics: risk of severe hyperkalemia.
• NSAIDs (e.g., ibuprofen, naproxen): may reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely)

• Lithium: increased lithium levels, risk of toxicity.
• Diuretics (thiazides): may enhance hypotensive effect and potassium loss.
• CYP2C9 inhibitors (e.g., fluconazole): may increase Irbesartan plasma concentrations.